COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes
substantial morbidity and mortality. There is currently no vaccine to prevent COVID-19 or
therapeutic agent to treat COVID-19. This clinical trial is designed to evaluate potential
therapeutics for the treatment of hospitalized COVID-19.
We hypothesis that chloroquine slows viral replication in patients with COVID-19, attenuating
the infection, and resulting in more rapid declines in viral load in throat swabs. This viral
attenuation should be associated with improved patient outcomes. Given the enormous
experience of its use in malaria chemoprophylaxis, excellent safety and tolerability profile,
and its very low cost, if proved effective then chloroquine would be a readily deployable and
affordable treatment for patients with COVID-19.
The study is funded and leaded by The Ministry of Health, Vietnam.
Phase:
Phase 2
Details
Lead Sponsor:
Oxford University Clinical Research Unit, Vietnam
Collaborators:
Can Gio COVID Hospital, Vietnam Cho Ray Hospital Cho Ray Hospital, Vietnam Cu Chi COVID Hospital, Vietnam Department of Health, Ho Chi Minh city Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam Ministry of Health, Vietnam National Hospital for Tropical Diseases, Hanoi, Vietnam